https://www.selleckchem.com/pr....oducts/Vorinostat-sa
Assessments will be conducted at baseline, prior to potential alteration of treatment (~4 months postbaseline), at completion of the intervention (maximum 6 months postbaseline) and 3-month and 6-month postintervention (maximum 9 and 12 months postbaseline). The EXPAN trial has been approved by Edith Cowan University (reference no. 2020-02011-LUO), Sir Charles Gairdner Hospital (reference no. RGS 03956) and St John of God Subiaco Hospital (reference no. 1726). The study results will be presented at national/international confere
Like
Comment
Share
